– Enrolled patients will receive medication for up to 24 weeks; 90 sites planned for North America and Europe – CHICAGO, March 1, 2023 – Emalex Biosciences announced that the first patient was dosed in its Phase 3 clinical trial evaluating ecopipam for the treatment of … Read more
– Study data shows investigational new drug, ecopipam, reduced total number of tics by 30% compared to placebo – CHICAGO—January 11, 2023 – A Phase 2b clinical trial involving more than 150 children and adolescents with Tourette syndrome found ecopipam significantly reduced the total number of … Read more
– Clinical stage biopharmaceutical company completes upsized, oversubscribed Series D financing from leading life sciences investors – CHICAGO—November 3, 2022 – Emalex Biosciences announced the closing of an upsized and oversubscribed $250 million Series D funding round that will fund a Phase 3 clinical trial … Read more
– Findings show investigational drug reduces tics by 30%; Data presentation April 5 – Chicago, March 31, 2022 – Emalex Biosciences, Inc. (“Emalex”), a biopharmaceutical company focused on developing treatments for central nervous system (CNS) movement disorders and fluency disorders, will present an abstract — … Read more
– License agreement secures potential research of ecopipam for one of the most common neurological sensory disorders – Chicago, March 1, 2022 – Emalex Biosciences, Inc. (“Emalex”), a biopharmaceutical company focused on developing treatments for central nervous system (CNS) movement disorders and fluency disorders, today … Read more